Evogene

Evogene Receivables

The Accounts Receivable of Evogene (EVGN) as of Nov 2, 2026 is 1.09 M USD. In the previous year, Accounts Receivable was 357,000.00 USD — a change of 205.60% (higher).

Receivables

1.09 MUSD

YoY

205.60%

Last updated:

Accounts Receivable of Evogene is 2024 1.09 M USD. Accounts Receivable of Evogene was 2023 357,000.00 USD. It decreases by 205.60% higher compared to the previous year.

The Evogene Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
100,000.00 USD
Jan 1, 2018
200,000.00 USD
Jan 1, 2019
100,000.00 USD
Jan 1, 2020
200,000.00 USD
Jan 1, 2021
300,000.00 USD
Jan 1, 2022
300,000.00 USD
Jan 1, 2023
357,000.00 USD
Jan 1, 2024
1.09 M USD
The Evogene Receivables history
YEARReceivablesYoY
1.09 MUSD+205.60%
357,000.00USD+19.00%
300,000.00USD0.00%
300,000.00USD+50.00%
200,000.00USD+100.00%
100,000.00USD-50.00%
200,000.00USD+100.00%
100,000.00USD-50.00%
200,000.00USD-92.59%
2.70 MUSD+125.00%
1.20 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evogene Stock analysis

What does Evogene do? Evogene Ltd is an Israeli biotechnology company that focuses on the application of computational biology and genomics to agriculture and biology. The company originated from a spin-off of the Weizmann Institute of Science and was founded in 2002. Today, it is a leading global provider of biotechnology solutions for the agriculture and biotechnology industry. Evogene's business model is based on providing innovative technologies and services for its customers, aiming to improve plant development, particularly in terms of resistance to environmental stress factors and pests. To achieve this, the company utilizes modern biotechnology methods and leverages artificial intelligence. It employs advanced machine learning and large-scale data analysis techniques to gain a better understanding of underlying biological processes. Evogene operates in three core areas: agricultural biotechnology, drug discovery biotechnology, and biomaterials. The company is capable of offering customized biological solutions tailored to the specific needs of its customers. Agricultural biotechnology is one of Evogene's key sectors. It utilizes state-of-the-art technologies and methods to generate plant resistance to pests and environmental factors. With the help of a reliable pipeline of innovative products such as seeds, biostimulants, and fertilizers, Evogene aims to play an important role in food security, environmental sustainability, and resilience to climate change. The company has a strong product pipeline aimed at improving nutrient efficiency of crops while reducing environmental impact from pesticide and fertilizer use. One such product resulting from this pipeline is EvoCanna, which utilizes modern genomics methods to optimize hemp plants in terms of phytocannabinoid biosynthesis. The goal of Evogene's drug discovery biotechnology and biomaterials sector is to develop innovative and effective medicines for diseases such as cancer and obesity. The company utilizes modern machine learning and large-scale data analysis methods to identify the potential of new drug candidates. In the biomaterials sector, Evogene aims to develop innovative technologies and solutions for better and more sustainable use of natural resources. An important application of this concept is biostimulants, which can improve the growth rate, stress tolerance, and yield of crops. Additionally, the company can offer new materials and environmentally friendly solutions in the packaging industry. Overall, Evogene has achieved impressive success in recent years and established itself as a leading biotechnology company. By utilizing cutting-edge technologies, methods, and scientific concepts, particularly artificial intelligence and machine learning, and by operating as a responsible company in the fields of agriculture, biomaterials, and programming, Evogene is able to offer innovative biotechnological solutions. The company is currently well-equipped and has a promising pipeline of groundbreaking innovation projects that embody the desire for a sustainable worldview. Evogene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evogene stock

Accounts Receivable of Evogene is 1.09 M USD in 2024.

Accounts Receivable of Evogene changed from 357,000.00 USD to 1.09 M USD, representing a 205.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Evogene since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Evogene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Evogene

All Key Metrics — Evogene